Light Mode
$0.0004 ↑ +0.0001 (+33.33%) Trading Up from the previous close of $0.0003, and at the day’s high of $0.0004
-0.03 (-98.43%) / 6M
Momentum, market sentiment, and recent alerts
WINT reads n/a: price sits below both the 20- and 200-day averages, the 12-month move is -99.7%.
No alerts for WINT in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
